Page 128 - Read Online

Komzak et al. Mini-invasive Surg 2021;5:13 I http://dx.doi.org/10.20517/2574-1225.2020.103 Page 13 of 14

This device is designed to reduce IOP by shunting aqueous fluid onto the ocular surface via a clear corneal
[29]
incision. There are currently no clinical trials on this device .

CONCLUSION
Minimally invasive glaucoma surgery has, for several years, been a disrupting force in the area of glaucoma
management and is a therapy that has effectively established itself between medical management and more
invasive glaucoma surgery. MIGS offer significant advantages in terms of safety and efficacy for the patient
with mild to moderate glaucoma and a significant medication burden. As this area of glaucoma surgery
continues to grow, so too will the evidence in support of MIGS as a legitimate intermediate step in the
glaucoma management pathway.

DECLARATIONS
Authors’ contributions
Made substantial contributions to conception and design of the study and performed data analysis and
interpretation: Komzak K, Rothschild P, Hooshmand J, Allen P, Toh T

Availability of data and materials
Not applicable.

Financial support and sponsorship
None

Conflicts of interest
All authors declared that there are no conflicts of interest

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Weinreb RN, Aung T, Medeiros FA. The Pathophysiology and Treatment of Glaucoma. JAMA 2014;311:1901-11.
2. McClelland JF, Bodle L, Little JA. Investigation of medication adherence and reasons for poor adherence in patients on long-term
glaucoma treatment regimes. Patient Prefer Adherence 2019;13:431-9.
3. Eldaly MA, Bunce C, Elsheikha OZ, Wormald R. Non-penetrating filtration surgery versus trabeculectomy for open-angle glaucoma.
Cochrane Database Syst Rev 2014:CD007059.
4. Samuelson TW, Chang DF, Marquis R, et al. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle
glaucoma and cataract: The HORIZON study. Ophthalmology 2019;126:29-37.
5. Hooshmand J, Rothschild P, Allen P, Kerr NM, Vote BJ, Toh T. Minimally invasive glaucoma surgery: Comparison of iStent with iStent
inject in primary open angle glaucoma. Clin Exp Ophthalmol 2019;47:898-903.
6. Ferguson TJ, Ibach M, Schweitzer J, Karpuk KL, Stephens JD, Berdahl JP. Trabecular micro-bypass stent implantation with cataract
extraction in pigmentary glaucoma. Clin Exp Ophthalmol 2020;48:37-43.
7. Ferguson TJ, Swan R, Ibach M, Schweitzer J, Sudhagoni R, Berdahl JP. Trabecular microbypass stent implantation with cataract
extraction in pseudoexfoliation glaucoma. J Cataract Refract Surg 2017;43:622-6.
8. Ahmed IIK, Fea A, Au L, et al. A prospective randomized trial comparing hydrus and iStent microinvasive glaucoma surgery implants for
standalone treatment of open-angle glaucoma: The COMPARE study. Ophthalmology 2020;127:52-61.
9. Katz LJ, Erb C, Carceller Guillamet A, et al. Long-term titrated IOP control with one, two, or three trabecular micro-bypass stents in